Tower Research Capital LLC TRC Increases Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Tower Research Capital LLC TRC raised its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 7,944.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 6,999 shares of the company's stock after buying an additional 6,912 shares during the quarter. Tower Research Capital LLC TRC's holdings in Krystal Biotech were worth $1,096,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the business. FMR LLC grew its stake in shares of Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after purchasing an additional 21,133 shares during the period. Vanguard Group Inc. boosted its stake in shares of Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after purchasing an additional 28,707 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after buying an additional 62,178 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Krystal Biotech by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company's stock valued at $38,095,000 after buying an additional 2,954 shares during the period. Finally, Norges Bank acquired a new stake in Krystal Biotech during the fourth quarter worth approximately $34,391,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on KRYS. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Chardan Capital lifted their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Finally, HC Wainwright lifted their target price on Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a report on Monday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech currently has an average rating of "Buy" and an average target price of $222.71.

Insiders Place Their Bets

In related news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded down $1.47 on Wednesday, hitting $169.10. 32,118 shares of the stock were exchanged, compared to its average volume of 294,818. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The stock has a market capitalization of $4.89 billion, a price-to-earnings ratio of 56.56 and a beta of 0.75. The company's 50-day moving average price is $176.00 and its 200 day moving average price is $171.49.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. During the same period in the prior year, the business earned $0.30 EPS. Krystal Biotech's revenue for the quarter was up 116.4% compared to the same quarter last year. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).